Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C→T polymorphism in MTHFR

Journal of Hypertension

Volumn 28, Issue 3, 2010, Pages 478-486

  Horigan, Geraldine ^a   McNulty, Helene ^a   Ward, Mary ^a   Strain, J J J ^a   Purvis, John ^b   Scott, John M ^c  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ALTNAGELVIN HOSPITAL   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Blood pressure; Cardiovascular disease; Methylenetetrahydrofolate reductase; Nutrition; Riboflavin

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO; RIBOFLAVIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE;

EID: 77149145514     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328334c126     Document Type: Article

References (43)

1. Wilcken B, Bamforth F, Li Z, Ritvanen A, Redlund M, Stoll C, et al. Geographical and Ethnic variation of the 677C>T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 2003; 40: 619-625.
2. Yamada K, Chen Z, Rosen R, Mathews RG. Effects of common polymorphism on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 2001; 98:14853-14858.
3. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
4. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.
5. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000; 46:1065-1071.
6. McNulty H, McKinley MC, Wilson B, Mc Partlin J, Strain JJ, Weir DG, Scott JM. Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr 2002; 76:436-441.
7. Hustad S, Midttun Ø, Schneede J, Vollset SE, Grotmol T, Ueland PM. The methylenetetrahydrofolate reductase 677!T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. Am J Hum Genet 2007; 80:846-855.
8. McNulty H, Dowey le RC, Strain JJ, Dunne A, Ward M, Molloy A, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C>T polymorphism. Circulation 2006; 113:74-80.
9. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202-1206. (Pubitemid 35398783)
10. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C>T polymorphism and risk ofcoronary heart disease:a meta-analysis. JAMA 2002; 288:2023-2031.
11. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C>T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate. BMJ 2005; 331:1053-1056.
12. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876-1882.
13. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-575.
14. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578-1588.
15. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567-1577.
16. Rodriguez-Esparragon F, Hernandez-Perera O, Rodriguez-Perez JC, Anabitarte A, Diaz-Cremades JM, Losada A, et al. The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values. Clin Exp Hypertens 2003; 25:209-220.
17. Inamoto N, Katsuya T, Kokubo Y, Mannami T, Asai T, Baba S, et al. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 2003; 34:1628-1633.
18. Jiang S, Hsu YH, Xu X, Xing C, Niu T, Zhang Y, et al. The C677T polymorphism of the methylentetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res 2004; 113:361-369.
19. Ravera M, Viazzi F, Berruti V, Leoncini G, Zagami P, Bezante G, et al. 5, 10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. Am J Hypertens 2001; 14:371-376.
20. Nakata Y, Katsuya T, Takami S, Sato N, Fu Y, Ishikawa K, et al. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens 1998; 11:1019-1023.
21. Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet 2007; 15:1239-1245.
22. Leino A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx analyzer. Clin Chem 1999; 45:569-571.
23. Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods Enzymol 1997; 281:43-53.
24. Kelleher BP, Broin SD. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. J Clin Pathol 1991; 44:592-595.
25. Bates CJ, Pentieva KD, Prentice A, Mansoor MA, Finch S. Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over. Br J Nutr 1999; 81:191-201.
26. Powers HJ, Bates CJ, Prentice AM, Lamb WH, Jepson M, Bowman H. The relative effectiveness of iron and iron with riboflavin in correcting a microcytic anaemia in men and children in rural Gambia. Hum Nutr Clin Nutr 1983; 37:413-425.
27. Tabachnik BG, Fidell LS. Using multivariate statistics, 3rd ed. New York, NY: Harper Collins College Publishers; 1996.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 2003; 42:1206-1252.
29. Hypertension: uncontrolled and conquering the world [editorial]. Lancet 2007; 370:539.
30. MacMahon S, Peto R, Collins R, Godwin J, MacMahon S, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1: Prolonged differences in blood pressure-differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
31. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual studies for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
32. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274:1526-1533.
33. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96:1745-1749.
34. Budge MM, de Jager C, Hogervorst E, Smith AD. Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J Am Geriatr Soc 2002; 50:2014-2018.
35. Limm U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156:1105-1113.
36. Sundstrom J, Sullivan L, D'Agostino RB, Jacques PF, Selhub J, Rosenberg IH, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension 2003; 42:1100-1105.
37. Fakhrzadeh H, Ghotbi S, Pourebrahim R, Heshmat R, Nouri M, Shafaee A, Larijani B. Plasma homocysteine concentration and blood pressure in healthy Iranian adults: the Tehran Homocysteine Survey (2003-2004). J Hum Hypertens 2005; 19:869-876. (Pubitemid 41637603)
38. Mc Mahon J, Skeaff M, Williams S, Green T. Lowering homocysteine with B vitamins has no effect on blood pressure in older adults. J Nutr 2007; 137:1183-1187.
39. Van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001; 21:2072-2079.
40. Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomised controlled trial. J Intern Med 2002; 252:497-503.
41. Williams C, Kingwell BA, Burke K, McPherson J, Dart AM. Folic acid supplementation for 3 weeks reduces pulse pressure and large artery stiffness independent of MTHFR genotype. Am J Clin Nutr 2005; 82:26-31.
42. Forman JP, Rimm EB, Stampfer MJ, Curhan GC. Folate intake and the risk of incident hypertension among US women. JAMA 2005; 293:320-329.
43. The National Diet and Nutrition Survey (NDNS): Adults aged 19 to 64 years. London: The Stationery Office, 2004.